Mounjaro (tirzepatide) / Eli Lilly, Cipla - LARVOL DELTA

Delayed Hypersensitivity Reaction to Tirzepatide Confirmed by Intradermal Testing (AAAAI 2026) - "While gastrointestinal adverse effects are well recognized, cutaneous reactions are less commonly described. Identifying whether a reaction is IgE- or T-cell–mediated is essential, as only IgE-mediated processes pose risk for anaphylaxis."

Diabetes • Immunology • Metabolic Disorders

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance (Eli Lilly Press Release) - "In Q4 2025, worldwide revenue was $19.3 billion, an increase of 43% compared with Q4 2024, driven by a 46% increase in volume, partially offset by a 5% decrease due to lower realized prices. Key Products[1] revenue grew to $13.8 billion in Q4 2025, led by Mounjaro and Zepbound...Revenue outside the U.S. increased 43% to $6.4 billion, driven by a 38% increase in volume and to a lesser extent a 4% favorable impact on foreign exchange rates. The volume increase outside the U.S. was driven primarily by Mounjaro, partially offset by Jardiance."

Commercial • CNS Disorders • Congestive Heart Failure • Inflammatory Bowel Disease • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Nation's Largest Thyroid Cancer Center Publishes White Paper Finding No Convincing Evidence That GLP-1 Medications Cause Common Thyroid Cancers (PRNewswire) - "Comprehensive review aims to clarify growing public concern around Ozempic, Wegovy, and Mounjaro...A newly released white paper from the Clayman Thyroid Center offers a comprehensive review of the scientific evidence and concludes that the best available human data do not show these medications cause (or have any effect upon) the most common types of thyroid cancer....According to the Clayman Thyroid Center's review, major international cohort studies and meta-analyses have not found increased thyroid cancer rates among GLP-1 users. Some studies showing possible 'associations' may be explained by detection bias."

Clinical • Obesity • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

Repositioning dual GLP-1/GIP receptor agonists for the treatment of colitis and colitis-associated cancer (CAC). (ECCO-IBD 2026) - "These findings imply that Tirzepatide could be a promising candidate for linking metabolic and immune pathways in the treatment of inflammation-related colon cancer. As research progresses, repositioning Tirzepatide for patients with these complex conditions may transform treatment strategies for IBD."

Immunology • Inflammatory Bowel Disease • CCND1 • CDKN1A • IL1B • IL6 • LCN2

Effectiveness and Safety of GLP-1 Receptor Agonists in Reducing Ostomy Output Among IBD Patients with Ileostomies (ECCO-IBD 2026) - "(Table 1). Conclusion GLP-1RAs in IBD patients with ileostomy appear to be effective in reducing ostomy output, BMI reduction, and are generally well tolerated."

Clinical • Inflammatory Bowel Disease • CRP

Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study. (PubMed, Gastroenterol Hepatol (N Y)) - No abstract available

Journal • Real-world evidence • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Mounjaro Launches in NZ for Obesity, Type 2 Diabetes (Mirage News) - "The medicine was evaluated under the Medsafe priority review pathway, which is a fast-track pathway for medicines of clinical significance that could be useful to help meet current Public Health challenges."

Launch non-US • Obesity • Type 2 Diabetes Mellitus

Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes. (PubMed, Ophthalmol Retina) - "Among patients with T2D taking a GLP-1RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving interventions, and NAION compared to GLP-1RAs without GIP activity. These findings support a favorable ocular safety profile for tirzepatide, though confirmation in prospective studies is warranted."

Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Hematological Disorders • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders • Type 2 Diabetes Mellitus

Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures. (PubMed, J Clin Endocrinol Metab) - "SEM/TIR use was associated with greater annualized TH bone loss in patients without DM, whereas TH bone loss was comparable between GLP-1 RA and controls in patients with DM. These findings suggest GLP-1 RA's effects on bone may differ by DM status, with weight loss driving bone loss in patients without DM."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A Fluorescent Probe-Based Platform for Precise Pharmaceutical Analysis and Quality Assessment of Tirzepatide. (PubMed, Luminescence) - "Tirzepatide, a first-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a breakthrough in the management of type 2 diabetes and obesity...Validation in accordance with ICH guidelines confirmed the method's excellent linearity over 0.1-20 μg/mL (r = 0.9999), with a detection limit of 0.012 μg/mL and a quantitation limit of 0.036 μg/mL, alongside outstanding precision (RSD < 1%) and accuracy. Furthermore, greenness assessment using multiple evaluation tools confirmed the environmentally friendly nature of the method, highlighting its suitability for routine quality control, pharmacokinetic studies, and potential application to future GIP/GLP-1-based therapies."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. (PubMed, Cancers (Basel)) - "In the first analysis, adult patients with pre-existing CP were identified and stratified by use of a GLP-1 RA (semaglutide, dulaglutide, tirzepatide, exenatide, liraglutide, lixisenatide, and albiglutide). Propensity score matching (PSM) was conducted between GLP1-RA users and non-users, matching for age, sex, race, tobacco use, alcohol use, hypertension, hyperlipidemia, obesity, and pancreatic cysts...Given the elevated cancer risk in CP, these findings suggest a potential beneficial effect of GLP-1RA use in this high-risk population. Prospective studies will be important to further analyze and confirm this potential benefit."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor • Type 2 Diabetes Mellitus

Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial. (PubMed, J Surg Res) - "Completion of this pilot RCT will provide data to support initiation of a multicenter RCT to determine therapeutic efficacy, and mechanisms of action, by which patients could benefit from preoperative treatment with tirzepatide."

Journal • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity

Mounjaro: “Q4 2025 Mounjaro sales increased $3.9B (Eli Lilly) - Q4 2025 Results

Commercial • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide (PubMed, Probl Endokrinol (Mosk)) - "The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Mounjaro: Primary completion and completion of P3 SURMOUNT-MMO trial (NCT05556512) for obesity in Oct 2027 (Eli Lilly) - Q4 2025 Results: Primary completion of P3 SYNERGY-Outcomes trial (NCT07165028) in adults with MASLD in Aug 2030; Completion of P3 SYNERGY-Outcomes trial in adults with MASLD in Aug 2032

Trial completion date • Trial primary completion date • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Mounjaro: Primary completion and completion of P3 SURMOUNT-MAINTAIN trial (NCT06047548) for obesity in May 2026 (Eli Lilly) - Q4 2025 Results: Primary completion of P3 SURMOUNT-ADOLESCENTS trial (NCT06075667) for obesity in May 2026; Completion of P3 SURMOUNT-ADOLESCENTS trial for obesity in Jul 2029

Trial completion date • Trial primary completion date • Obesity

RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Both required insulin during pregnancy and delivered healthy babies at 38 weeks...Tirzepatide may be a beneficial therapeutic option for managing patients with RFX6-MODY who have adequate β-cell function. Pregnancy management in patients with RFX6-MODY is similar to type 2 DM, although higher insulin doses may be required."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction. (PubMed, JCEM Case Rep) - "While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combined GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs), like tirzepatide, are effective for weight loss and diabetes management, their unsupervised use, especially alongside ketosis-inducing diets, may lead to serious risks such as EDKA. This report emphasizes the need for medical supervision in weight management, particularly when combining medications such as tirzepatide with dietary interventions, like IF and low-carbohydrate diets."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders

CGM METRICS IN ADULTS WITH TYPE 1 DIABETES USING TIRZEPATIDE FOR >12 MONTHS (ATTD 2026) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

THE RELATIONSHIP BETWEEN ADVERSE EVENTS AND PATIENT PROFILES IN TIRZEPATIDE AND SEMAGLUTIDE USERS WITH TYPE 1 DIABETES IN REAL-WORLD SETTINGS (ATTD 2026) - No abstract available

Adverse events • Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal. (PubMed, BMC Chem) - "The obtained linearity range for both TIR and SEM was 1-500 µg/mL with correlation coefficients > 0.9999. An in-depth six- edged sustainability assessment of the proposed method was conducted using greenness, whiteness, blueness and violet innovation metrics was performed using Analytical Greenness Metric (AGREE), Modified Green Analytical Procedure Index (MoGAPI), Analytical Eco-scale, Analytical Green Star Area (AGSA), Carbon Footprint Reduction Index (CaFRI), Whiteness using RGB algorithm, Blue Applicability Grade Index (BAGI), Click Analytical Chemistry Index (CACI), Violet Innovation Grade Index (VIGI) tools and Stability Toolkit for the Appraisal of Bio/Pharmaceuticals' Level of Endurance (STABLE)."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

THE COMBINED EFFECT OF RT-CGM AND TIRZEPATIDE ON HBA1C IN PEOPLE WITH TYPE 2 DIABETES ON INTENSIVE INSULIN OR BASAL INSULIN THERAPIES (ATTD 2026) - No abstract available

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

POSTER OF DISTINCTION: GLUCAGON-LIKE 1 RECEPTOR AGONIST USE WAS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LARGE REAL-WORLD DATABASE STUDY (CCCongress 2026) - "Introduction: The utilization of glucagon-like peptide 1 receptor agonists (GLP-1RA) is rising for the treatment of obesity, with emerging data to suggest that they may also exert anti-inflammatory effects beyond weight loss...GLP-1RA exposure was defined as having a GLP-1RA (liraglutide, semaglutide, tirzepatide) ordered or administered at least twice... The use of GLP-1 receptor analogs was associated with improved IBD-specific outcomes in patients with UC and CD. Further study is needed to better define the true impact of GLP1RA on IBD-specific outcomes, ideally with more granular measures of disease activity."

Clinical • Real-world • Real-world evidence • Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Ulcerative Colitis

A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: Peking University Third Hospital

New trial • Real-world evidence • Dermatology • Immunology • Obesity • Psoriasis

Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation. (PubMed, Vascul Pharmacol) - "Our findings indicate that tirzepatide curbs the development of TAAD in mice. The underlying mechanism likely involves the suppression of the NLRP3 inflammasome priming, a consequent reduction in vascular inflammation, and the preservation of the contractile state of VSMC. These findings highlight its potential as a novel therapeutic strategy for TAAD."

Journal • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • CNN1 • IL1B • IL6 • NLRP3